

Research Infrastructures and COVID-19 Research



ACCELERATE is funded by the European Union Framework Programme for Research and Innovation Horizon 2020, under grant agreement 731112



Research Infrastructures and COVID-19 Research

Responses to the questionnaire

EATRIS

EATRIS, the European Research Infrastructure for Translational Medicine, aims to accelerate the translation of promising scientific discoveries into benefits for patients. EATRIS focuses on bridging the innovation gap between the lab and the clinic and offers services and expertise to increase the potential of research to successfully reach patients.

SERVICE/S IMPLEMENTED

EATRIS provides access to technologies, expertise and resources from 105 research institutes across 13 countries for academic and industrial researchers carrying out translational research (main focus on pre-clinical and early clinical research). In addition, EATRIS fosters academia-industry collaboration by initiating and managing public-private partnerships with large pharma and SMEs.

What stage in COVID-19 intervention your RI is addressing?

Vaccine research; regulatory support for scientific advice procedure; Immunomonitoring and virological assays; High throughput screening supporting diagnostics, genotyping, phenotyping and drug repurposing; Clinical isolation units; Expertise on pharmacology and protein-drug interaction modelling; Advanced preclinical animal models including Non Humane Primates

Instruments/databases involved:

Instruments described above

How is the proposal submitted?

Via email to christieken[at]eatris.eu

Who evaluates the proposal?


EATRIS Scientific Director assisted by Scientific teams at EATRIS Coordination and Support Office

Is the submission continuous, or linked to a deadline?

Continuous

What is the estimated time from the submission to the access / service provision?

48-72 hours



Research Infrastructures and COVID-19 Research



ACCELERATE is funded by the European Union Framework Programme for Research and Innovation Horizon 2020, under grant agreement 731112



CHARACTERISTICS OF THE ACCESS

Restrictions: NO

In the case of analytical facilities, modality of access allowed: Remote and on-site access

If on-site access is allowed, is mobility support available?	NO
Is the access free for non-proprietary research?	NO
Is commercial access available at reduced prices?	NO
Are there limitations regarding the type of samples?	NO
Are there special requirements for shipment of the samples?	YES
Are there specific requirements regarding the preparation or handling of the samples?	YES

Additional comments related to the questions above: Questions above cannot be answered with Yes/No as the answer depends on the particular services and the institution's own access rules.

ACCESSIBILITY OF THE PUBLICATION AND DATA

Is there any requirement to publish in open access journals?	NO
Is the data generated associated to metadata and is it publicly available?	NO
If yes, what is the embargo period?	Depends on the institution
Where is the data or metadata published? (e.g. in the institution's catalogue, in other open data repositories, etc).	Similar comment as previously; these questions cannot be answered by yes or no for all services provided by our institutions.
Do you have further comments about data or metadata?	